| 1 Tranquillisation or asleep: 1. tranquillised/sleep within 120 minutes |
1 |
228 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.93, 1.09] |
| 2 Tranquillisation or asleep: 2. time to tranquillisation/sleep |
|
|
Other data |
No numeric data |
| 3 Global state: use of additional medication |
2 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 3.1 Midazolam administered initially |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
3.26 [0.69, 15.37] |
| 3.2 By 30 minutes |
1 |
27 |
Risk Ratio (M‐H, Random, 95% CI) |
0.45 [0.20, 1.01] |
| 3.3 By 60 minutes |
2 |
255 |
Risk Ratio (M‐H, Random, 95% CI) |
0.37 [0.16, 0.90] |
| 3.4 By 90 minutes |
1 |
27 |
Risk Ratio (M‐H, Random, 95% CI) |
0.47 [0.02, 10.63] |
| 4 Global state: no overall improvement ‐ by 30 days |
1 |
40 |
Risk Ratio (M‐H, Random, 95% CI) |
0.67 [0.29, 1.52] |
| 5 Adverse effects |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 5.1 Cardiovascular ‐ hypotension |
1 |
228 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.80 [0.30, 26.49] |
| 5.2 Cardiovascular ‐ hypotension/desaturation |
1 |
228 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.80 [0.12, 67.98] |
| 5.3 Central nervous system ‐ extrapyramidal adverse effects |
1 |
228 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.80 [0.12, 67.98] |
| 5.4 Central nervous system ‐ oversedation |
1 |
228 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.80 [0.12, 67.98] |
| 5.5 Staff injuries |
1 |
228 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.56 [0.14, 2.29] |
| 6 Mental state: Average score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) |
1 |
40 |
Mean Difference (IV, Fixed, 95% CI) |
0.11 [‐0.07, 0.29] |
